Premium
Management of haemophilic arthropathy
Author(s) -
BOSSARD D.,
CARRILLON Y.,
STIELTJES N.,
LARBRE J.P.,
LAURIAN Y.,
MOLINA V.,
DIRAT G.
Publication year - 2008
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2008.01734.x
Subject(s) - medicine , haemophilia , arthropathy , synovectomy , clotting factor , context (archaeology) , physical therapy , synovitis , rehabilitation , intensive care medicine , surgery , arthritis , osteoarthritis , alternative medicine , rheumatoid arthritis , paleontology , pathology , biology
Summary. Despite the tremendous benefit offered by primary prophylaxis, recurrent joint bleeding with progression to chronic synovitis and haemophilic arthropathy is still a daily concern for the multidisciplinary health care teams managing patients with severe haemophilia or haemophilia complicated by inhibitor development. Advanced stages of arthropathy could be prevented by regular assessment of musculoskeletal status and thus early detection of symptoms, daily rehabilitation exercises at home, and implementation of appropriate physiotherapy and medical training. Patient’s education and psychological counselling are crucial. New tools such as magnetic resonance imaging are promising for the monitoring of these patients and might promote early detection of arthropathy and thus appropriate preventive measures to avoid further joint deterioration can be implemented. Medical synovectomy such as radionucleide synoviorthesis is a simple and non‐invasive procedure that often delays the need for surgery which despite considerable improvement in techniques and postoperative rehabilitation remains a high‐risk strategy in patients with severe haemophilia, especially those with inhibitors. In these high risk patients, availability of specific clotting factors such as activated prothrombin complex concentrate (FEIBA ® , Baxter, Vienna, Austria) and more recently, recombinant factor VIIa (rFVIIa, NovoSeven ® , Bagsvaerd, Denmark) has allowed to perform effective and safe orthopaedic procedures. The on‐going EUREKA study will undoubtedly provide additional information about the optimal use of rFVIIa in this context.